Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909623 | 0.79 | HTR2A (0.34) | HTR2AHTR2CHTR2BSIGMAR1BTK | |
| SCHEMBL20893422 | 0.76 | HTR2A (0.38) | HTR2AHTR2CHTR2BSIGMAR1BTK | |
| SCHEMBL29185139 | 0.76 | POLB (0.47) | MAPTSMN1; SMN2HTR2AHTR2CHTR2B | |
| SCHEMBL15739458 | 0.76 | POLB (0.47) | MAPTSMN1; SMN2HTR2AHTR2CHTR2B | |
| SCHEMBL14617840 | 0.76 | HCAR2 (0.44) | HTR2AHTR2CHTR2BSIGMAR1BTK | |
| SCHEMBL18904835 | 0.76 | METAP1 (0.33) | SMN1; SMN2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL17426067 | 0.76 | ALDH1A1 (0.33) | ALDH1A1MAPTHPGDHTR2AHTR2C | |
| SCHEMBL22036986 | 0.74 | ALDH1A1 (0.37) | KDM4EALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL20415397 | 0.71 | MAPT (0.45) | KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL15715697 | 0.70 | DPP7 (0.39) | HTR2AHTR2CHTR2BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697657-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-20210122764-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | MERCK SHARP & DOHME LLC | 2021-04-29 | — | — | US | disclosed |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697657-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | KDM4E 2052/4885ALDH1A1 4169/4885MAPT 4839/4885 |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | SSB, MAPKAPK5, BCL9 | KDM4E 255/4885ALDH1A1 3332/4885MAPT 4128/4885 |
| US-20210122764-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | KRAS, NRAS, HRAS | KDM4E 2052/4885ALDH1A1 4169/4885MAPT 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.